The Effect of a Life-Style Intervention Program of Diet and Exercise on Irisin and FGF-21 Concentrations in Children and Adolescents with Overweight and Obesity.
Adolescent
Biomarkers
/ blood
Body Mass Index
Cardiometabolic Risk Factors
Child
Child, Preschool
Combined Modality Therapy
/ methods
Exercise Therapy
Feeding Behavior
Female
Fibroblast Growth Factors
/ blood
Fibronectins
/ blood
Follow-Up Studies
Healthy Lifestyle
Humans
Male
Overweight
/ blood
Pediatric Obesity
/ blood
Risk Assessment
/ methods
Treatment Outcome
Weight Loss
FGF-21
adolescence
childhood
irisin
obesity
overweight
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
13 Apr 2021
13 Apr 2021
Historique:
received:
25
02
2021
revised:
06
04
2021
accepted:
09
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
8
6
2021
Statut:
epublish
Résumé
Overweight and obesity in childhood and adolescence represent major public health problems of our century, and account for increased morbidity and mortality in adult life. Irisin and Fibroblast Growth Factor 21 (FGF-21) have been proposed as prognostic and/or diagnostic biomarkers in subjects with obesity and metabolic syndrome, because they increase earlier than other traditional biomarkers. We determined the concentrations of Irisin and FGF-21 in children and adolescents with overweight and obesity before and after one year of a life-style intervention program of diet and physical exercise and explored the impact of body mass index (BMI) reduction on the concentrations of Irisin, FGF-21 and other cardiometabolic risk factors. Three hundred and ten (
Identifiants
pubmed: 33924457
pii: nu13041274
doi: 10.3390/nu13041274
pmc: PMC8070027
pii:
doi:
Substances chimiques
Biomarkers
0
FGF21 protein, human
0
FNDC5 protein, human
0
Fibronectins
0
Fibroblast Growth Factors
62031-54-3
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : This research has been co-financed by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH - CREATE - INNOVATE
ID : (project code: T1EDK-01386, MIS: 5030543, Acronym: PEDOBESITY)
Références
Diab Vasc Dis Res. 2018 May;15(3):263-269
pubmed: 29424246
Int J Obes (Lond). 2006 Dec;30(12):1775-81
pubmed: 16607382
J Clin Endocrinol Metab. 2015 Apr;100(4):1289-99
pubmed: 25625801
J Clin Endocrinol Metab. 2015 May;100(5):2123-30
pubmed: 25781361
Diabetes. 2014 Dec;63(12):4057-63
pubmed: 25008183
Acta Diabetol. 2014 Oct;51(5):705-13
pubmed: 24619655
J Diabetes Complications. 2016 Nov - Dec;30(8):1560-1565
pubmed: 27539885
J Clin Res Pediatr Endocrinol. 2017 Jun 1;9(2):124-131
pubmed: 28077341
Nutr Metab Cardiovasc Dis. 2018 Jul;28(7):756-764
pubmed: 29858156
Front Endocrinol (Lausanne). 2014 Jul 07;5:107
pubmed: 25071723
Trends Pharmacol Sci. 2015 Jul;36(7):461-70
pubmed: 26022934
Obesity (Silver Spring). 2015 Apr;23(4):729-32
pubmed: 25820255
Nature. 2012 Jan 11;481(7382):463-8
pubmed: 22237023
Front Med. 2019 Oct;13(5):511-530
pubmed: 31495905
J Clin Endocrinol Metab. 2012 Jun;97(6):2143-50
pubmed: 22438225
Obes Facts. 2019;12(1):25-39
pubmed: 30673672
Cytokine. 2017 Jun;94:8-13
pubmed: 28385328
J Clin Med. 2020 Feb 06;9(2):
pubmed: 32041319
J Clin Endocrinol Metab. 2012 Jul;97(7):E1224-8
pubmed: 22539584
Front Endocrinol (Lausanne). 2015 Sep 23;6:147
pubmed: 26441837
J Clin Endocrinol Metab. 2013 Dec;98(12):4899-907
pubmed: 24057291
J Clin Res Pediatr Endocrinol. 2014 Sep;6(3):129-43
pubmed: 25241606
J Am Diet Assoc. 2004 Apr;104(4):595-603
pubmed: 15054345
Clin Endocrinol (Oxf). 2014 Dec;81(6):862-70
pubmed: 24841294
Nutrients. 2015 Nov 13;7(11):9453-74
pubmed: 26580649
Nat Rev Endocrinol. 2017 Jun;13(6):324-337
pubmed: 28211512
Int J Endocrinol. 2014;2014:857270
pubmed: 24864142
Cell Metab. 2013 Sep 3;18(3):333-40
pubmed: 24011069
J Obes Metab Syndr. 2017 Sep;26(3):204-209
pubmed: 31089518
Biomed Res Int. 2017;2017:2628968
pubmed: 28553647
J Clin Endocrinol Metab. 2015 Aug;100(8):3004-10
pubmed: 26052728
J Clin Densitom. 2019 Apr - Jun;22(2):179-184
pubmed: 30228048
Nutr Metab (Lond). 2015 Sep 15;12:31
pubmed: 26379757
Pediatr Obes. 2016 Aug;11(4):299-305
pubmed: 26305484
BMJ Open. 2019 Aug 30;9(8):e028231
pubmed: 31473614
PLoS One. 2013 Apr 22;8(4):e61432
pubmed: 23630589
Obes Rev. 2017 Jun;18(6):603-634
pubmed: 28346723
J Pediatr Endocrinol Metab. 2019 Sep 25;32(9):921-928
pubmed: 31323006
Mol Neurobiol. 2018 Jun;55(6):4702-4717
pubmed: 28712011
J Endocr Soc. 2019 Feb 15;3(4):825-837
pubmed: 30963140
Sci Rep. 2015 May 18;5:10275
pubmed: 25985218
Cell Metab. 2012 Sep 5;16(3):387-93
pubmed: 22958921
J Clin Transl Endocrinol. 2015 Jun 1;2(2):77-82
pubmed: 26042208
Lancet. 2017 Dec 16;390(10113):2627-2642
pubmed: 29029897
Obesity (Silver Spring). 2014 Jul;22(7):1701-8
pubmed: 24644099
PLoS One. 2014 Jun 13;9(6):e100218
pubmed: 24926783
Obes Facts. 2019;12(2):244-258
pubmed: 31030201
Biochim Biophys Acta. 2000 Jun 21;1492(1):203-6
pubmed: 10858549
J Obes. 2018 Sep 12;2018:7461903
pubmed: 30298107
PLoS One. 2013 Apr 11;8(4):e60563
pubmed: 23593248
Pediatr Obes. 2012 Aug;7(4):284-94
pubmed: 22715120
Genes Dev. 2012 Feb 1;26(3):271-81
pubmed: 22302939
Horm Res Paediatr. 2020;93(2):94-107
pubmed: 32580197